Albert Einstein Israelite Hospital

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure

Retrieved on: 
Monday, September 12, 2022
YouTube, Health, Albert Einstein Israelite Hospital, Agriculture, Affordable Care Act, Twitter, Illumina, Inc., LinkedIn, IGF, Bill, Care Act 2014, Reproductive health, Strand Life Sciences, Instagram, Global health, Population health, Public health, Diagnosis, NASDAQ, Genomics, SAN, Research, Bill & Melinda Gates Foundation, DNA, Genome, Mobile phone, Medicine, Illumina, Facebook

SAN DIEGO, Sept. 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel of leading visionaries, titled "Architecting Health's Radically New Infrastructure," as part of its inaugural Illumina Genomics Forum being held in San Diego from September 28 through October 1. This main-stage session, taking place on Friday, September 30, will feature renowned experts addressing the cornerstone challenges and opportunities facing the health industry, including genomics literacy, equity, public health, and pathogen preparedness. 

Key Points: 
  • Moderated by Joao Bosco Oliveira, head of Genomics at Albert Einstein Hospital, the panel will include:
    "We are deeply humbled and absolutely thrilled to have these global leaders from across the genomics and health care ecosystem participating in our inaugural Illumina Genomics Forum," said Kathryne Reeves, chief marketing officer of Illumina.
  • Illumina previously announced that former US President Barack Obama will headline the forum in a fireside chat on the evening of Wednesday, September 28.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
  • To learn more,visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .

City of Hope and Hospital Israelita Albert Einstein Sign Agreement to Advance Cancer Care in Latin America

Retrieved on: 
Thursday, April 1, 2021
Research, Hospitals, Biotechnology, Other Education, Training, General Health, Health, Science, Education, Oncology, Albert Einstein, Albert Einstein Israelite Hospital, City of Hope, Hospital Israelita Albert Einstein

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America.

Key Points: 
  • City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America.
  • View the full release here: https://www.businesswire.com/news/home/20210401005185/en/
    The three-year agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert Einsteins oncology residents and clinical staff.
  • We hope to collaborate with our Latin American colleagues to improve cancer care outcomes not only in So Paulo, but also throughout Brazil and Latin America.
  • Hospital Israelita Albert Einstein has been ranked as the best hospital in Latin America by the America Economia Business Intelligence Unit for 12 years in a row.